Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
Greener
Mark
M
D002986:Clinical Trials as Topic; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing / Q000592:standards* / Q000639:trends; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D007783:Lactones; D013450:Sulfones; C116926:rofecoxib
Br J Clin Pharmacol. 1999 Oct;48(4):623-7
10583035
J Health Econ. 2003 Mar;22(2):151-85
12606142
Nat Rev Drug Discov. 2005 Jan;4(1):5-7
15690595
N Engl J Med. 2004 Oct 21;351(17):1707-9
15470193
Nat Rev Drug Discov. 2004 Apr;3(4):360-4
15060531